Nona aims to help global biopharmaceutical companies fast-track clinical trial initiation without compromising scientific rigor or quality standards
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
The portfolio includes foundational patents on the production, composition, and commercial use of NR
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
NUFYMCO BLA has been approved by the USFDA
Subscribe To Our Newsletter & Stay Updated
